Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada) + Lopinavir/ritonavir (kaletra) versus TDF-FTC (Truvada) + raltegravir (Isentress). A prospective, randomized, open clinical trial.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
Indications HIV infections
Focus Adverse reactions
Acronyms RAL-PEP

Most Recent Events

18 Mar 2016 Results published in the Journal of Antimicrobial Chemotherapy
25 May 2015 Status changed from recruiting to completed.
11 Apr 2012 Additional lead trial centre, investigator (Garcia Felipe, MD) identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight